1例安罗替尼致严重血小板降低伴皮下出血的病例分析
冯文娟
周文强 （ 宝鸡市第三人民医院 ）
https://doi.org/10.37155/2661-4766-0102-9Abstract
1例57岁女性患者在确诊肺腺癌后，经多方案化疗后症状有所缓解，后因白细胞降低及贫血，病情危重，无法耐受化疗，给予盐酸安罗替尼胶囊治疗。规律服药3月后，因气短来院就诊，血常规检查报危急值：血小板5×109/L，全身多处皮肤黏膜可见散在出血点，同时伴肉眼可见血尿，考虑为盐酸安罗替尼导致血小板降低引发出血所致。立即停用盐酸安罗替尼，给予对症治疗，一周后患者病情未见好转，出现进行性加重，家属拒绝进一步治疗，要求出院。
Keywords
安罗替尼; 血小板降低; 出血; 非小细胞肺癌; 药品不良反应Full Text
PDFReferences
[1]正大天晴药业集团股份有限公,盐酸安罗替尼胶囊说明书[Z]. (2018-05-08). https://www.cttq.com/product/zhongliu-detail-25102.htm.
[2]Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. 2018;654:77-86.
[3]Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018109(4):1207-1219.
[4]Li K, Han BH, Wang QM, Zhang L, Shi JH, Wang ZH, Cheng Y, He JX, Shi YK, Chen WQ, Wang XW, Luo Y, Nan KJ, Jin FG, Li BL, Wang J. OS outcomes to anlotinib in patients(pts) with refractory NSCLC of both wild-type(WT) and mutant EGFR[J]. J Clin Oncol. 2018,36:15_suppl,e21013-e21013.
[5]Han BH, Li K, Wang QM, Zhao YZ, Zhang L, Shi JH, Wang ZH, Cheng Y, He JX, Shi YK, Chen WQ, Wang XW, Luo L, Nan KJ, Jin FG, Li BL, Chen YL, Zhou JY, Wang DL. Third-line treatment:A randomized,double-blind,placebo-contr-olled phase Ⅲ ALTER-0303 study-Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC[J]. J Clin Oncol. 2017,35:15_suppl,9053-9053.
[6]CFDA.药品ADR报告和监测工作手册[EB/OL].[2013-12-15]. http://www.cdr-adr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426_5436.html.
[7]吴军.抗肿瘤血管生成药物不良反应的发生机制及处理[J].医学综述, 2016,22(16):3154-3157.
[8]中国医师协会肿瘤医师分会,中国临床肿瘤学会血管靶向治疗专家委员会,中国抗癌协会肿瘤靶向治疗专业委员会.盐酸安罗替尼治疗晚期非小细胞肺癌专家共识[J].中华医学杂志, 2018,98(44):3561-3567.
[9]廖彬池,杜婧.舒尼替尼致不良反应的文献分析[J].中国药房, 2017,28(35):4932-4935.
[10]史芳.贝伐珠单抗治疗恶性肿瘤的不良反应临床分析[J].医学理论与实践, 2017,30(23):3502-3503.
[11]CTCAE v4.0, Common Terminology Criteria for Adverse Events[EB/OL].[2011/09/01]http://www.calgb.org/Public/meetings/presentations/2009/sum-mer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf.
[12]中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志, 2016,37(2):89-93.
[2]Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. 2018;654:77-86.
[3]Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018109(4):1207-1219.
[4]Li K, Han BH, Wang QM, Zhang L, Shi JH, Wang ZH, Cheng Y, He JX, Shi YK, Chen WQ, Wang XW, Luo Y, Nan KJ, Jin FG, Li BL, Wang J. OS outcomes to anlotinib in patients(pts) with refractory NSCLC of both wild-type(WT) and mutant EGFR[J]. J Clin Oncol. 2018,36:15_suppl,e21013-e21013.
[5]Han BH, Li K, Wang QM, Zhao YZ, Zhang L, Shi JH, Wang ZH, Cheng Y, He JX, Shi YK, Chen WQ, Wang XW, Luo L, Nan KJ, Jin FG, Li BL, Chen YL, Zhou JY, Wang DL. Third-line treatment:A randomized,double-blind,placebo-contr-olled phase Ⅲ ALTER-0303 study-Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC[J]. J Clin Oncol. 2017,35:15_suppl,9053-9053.
[6]CFDA.药品ADR报告和监测工作手册[EB/OL].[2013-12-15]. http://www.cdr-adr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426_5436.html.
[7]吴军.抗肿瘤血管生成药物不良反应的发生机制及处理[J].医学综述, 2016,22(16):3154-3157.
[8]中国医师协会肿瘤医师分会,中国临床肿瘤学会血管靶向治疗专家委员会,中国抗癌协会肿瘤靶向治疗专业委员会.盐酸安罗替尼治疗晚期非小细胞肺癌专家共识[J].中华医学杂志, 2018,98(44):3561-3567.
[9]廖彬池,杜婧.舒尼替尼致不良反应的文献分析[J].中国药房, 2017,28(35):4932-4935.
[10]史芳.贝伐珠单抗治疗恶性肿瘤的不良反应临床分析[J].医学理论与实践, 2017,30(23):3502-3503.
[11]CTCAE v4.0, Common Terminology Criteria for Adverse Events[EB/OL].[2011/09/01]http://www.calgb.org/Public/meetings/presentations/2009/sum-mer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf.
[12]中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志, 2016,37(2):89-93.
Copyright © 2019 冯文娟，周文强
Publishing time:2019-12-20
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location